Key Takeaways
- A tirzepatide compounding pharmacy is a state-licensed facility that prepares tirzepatide injection in response to an individual patient prescription.
- Compounding pharmacies fall into two FDA categories: 503A (patient-specific) and 503B (outsourcing facilities that ship in larger quantities).
- Compounded tirzepatide is not FDA-approved and is not interchangeable with Mounjaro or Zepbound.
- Legitimate compounders use USP-grade active pharmaceutical ingredient sourced from FDA-registered manufacturers and produce in cleanrooms certified to USP <797> standards.
- The FDA's October 2024 declaration that tirzepatide is no longer in shortage changed which compounders can legally produce it under 503A and 503B rules.
Direct answer (40-60 words)
A tirzepatide compounding pharmacy is a state-licensed pharmacy that prepares custom tirzepatide injection in response to an individual patient prescription. Compounded tirzepatide is not FDA-approved. Following the FDA's October 2024 removal of tirzepatide from the drug shortage list, only 503A pharmacies producing for specific patient needs and 503B outsourcing facilities under specific conditions can legally compound it.
Table of contents
- The 30-second answer
- What compounding actually means in U.S. pharmacy law
- 503A vs 503B: the two types of compounding pharmacies
- How tirzepatide is compounded
- Why compounded tirzepatide exists at all
- The shortage list and what changed in October 2024
- How to verify a legitimate compounding pharmacy
- Red flags to avoid
- Cost difference vs brand Mounjaro and Zepbound
- Storage, shipping, and shelf life of compounded tirzepatide
- FAQ
- Footer disclaimers
What compounding actually means in U.S. pharmacy law
Pharmacy compounding is the practice of preparing a customized medication for an individual patient based on a prescription from a licensed provider. Compounding has existed since the earliest days of pharmacy, originally for tasks like converting an adult dose into a pediatric concentration or removing an allergen ingredient.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Compounding is regulated at the state level by state boards of pharmacy and at the federal level by the FDA under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
A compounded medication is not the same as an FDA-approved drug:
- An FDA-approved drug has gone through clinical trials, manufacturing inspections, and a New Drug Application or Biologics License Application.
- A compounded drug is prepared in response to a specific prescription using bulk active pharmaceutical ingredient (API).
- Compounded drugs are not subject to the same FDA review process as the brand-name product.
This distinction is the source of most confusion around compounded tirzepatide. Patients sometimes assume compounded tirzepatide is "generic Mounjaro" or "the same drug, just cheaper." It is not. Tirzepatide is patent-protected, and no FDA-approved generic exists. Compounded tirzepatide is a separate product made under a different regulatory framework.
For the related topic of compounded semaglutide color variations, see our why is my compounded semaglutide red guide.
503A vs 503B: the two types of compounding pharmacies
Federal law splits compounding into two categories.
503A pharmacies are traditional, state-licensed compounding pharmacies. They prepare medications in response to a specific prescription for a specific patient. They are regulated primarily by state boards of pharmacy and follow USP standards (USP <797> for sterile compounding, USP <795> for non-sterile compounding).
Key 503A characteristics:
- Patient-specific prescriptions required
- No requirement to register with the FDA as a manufacturer
- Inspected by state boards of pharmacy
- Cannot ship medications across state lines beyond limited "anticipatory" amounts (typically 5% of total prescription orders or as state law allows)
503B outsourcing facilities are a newer category created by the Drug Quality and Security Act of 2013. These are FDA-registered facilities that can produce compounded medications in larger batches without patient-specific prescriptions. They follow current Good Manufacturing Practice (cGMP) standards, similar to FDA-approved drug manufacturers.
Key 503B characteristics:
- FDA-registered and inspected
- Can ship across state lines without a specific prescription on file
- Must follow cGMP (more stringent than USP <797>)
- Can compound a drug only if it is on the FDA's bulk substance list, in shortage, or meets specific patient need exceptions
The distinction matters for tirzepatide because the rules under which a 503A or 503B can legally compound tirzepatide changed in October 2024.
How tirzepatide is compounded
The standard tirzepatide compounding process at a legitimate pharmacy follows these steps.
Sourcing. USP-grade tirzepatide active pharmaceutical ingredient is purchased from an FDA-registered API supplier. Each lot has a Certificate of Analysis (CoA) confirming purity, potency, and absence of impurities.
Reconstitution and dilution. The dry tirzepatide powder is reconstituted with sterile water for injection (USP) or another suitable diluent (often bacteriostatic water or a phosphate buffer) to a target concentration, commonly 5 mg/mL or 10 mg/mL.
Sterile filtration. The solution is passed through a 0.22 micron sterile filter inside an ISO Class 5 laminar flow hood.
Vial filling. The filtered solution is dispensed into individual sterile glass vials with rubber stoppers and aluminum crimp seals.
Quality testing. Pharmacies often test for sterility, endotoxin (LAL test), pH, potency by HPLC, and visual clarity. 503B facilities are required to perform additional cGMP testing on each batch.
Labeling and dispensing. Each vial is labeled with patient name, prescriber name, dose, concentration, lot number, beyond-use date, and storage instructions, then shipped to the patient.
The whole process from API receipt to patient shipment is typically 5 to 10 business days at a 503A pharmacy and longer at a 503B that operates on production batches.
Why compounded tirzepatide exists at all
The FDA permits compounding of drugs that are otherwise commercially available under specific conditions:
- The drug is on the FDA drug shortage list.
- The patient has a documented clinical need that the FDA-approved product cannot meet (e.g., allergy to an inactive ingredient, specific dose strength not commercially available).
- The compounding is for a 503B facility producing under specific bulk substance exemptions.
Tirzepatide was added to the FDA drug shortage list in December 2022. From that point until October 2024, both 503A and 503B compounding pharmacies could legally compound tirzepatide because the brand product was in shortage. This created the market for compounded tirzepatide telehealth services that emerged in 2023.
In October 2024, the FDA declared tirzepatide no longer in shortage. This change had immediate regulatory consequences for compounding (covered in the next section).
The patient-specific clinical need exception still allows compounding for individual patients who have documented reasons the brand product does not meet their needs (e.g., patients who require a different concentration than the brand pen delivers, or who have specific inactive-ingredient sensitivities).
The shortage list and what changed in October 2024
The FDA's October 2, 2024 announcement removed tirzepatide from the drug shortage list. The shortage had existed since December 2022 due to demand outpacing brand-name production capacity at Eli Lilly.
When a drug comes off the shortage list, two regulatory consequences follow:
For 503B outsourcing facilities: they must stop compounding the drug under the shortage exemption within 60 to 90 days of the FDA notice (the exact timeline varies by FDA enforcement policy). The Outsourcing Facilities Association sued the FDA over the timeline in October 2024, and the case is ongoing as of April 2026.
For 503A traditional compounders: they can continue to compound tirzepatide under the patient-specific clinical need exception, but they cannot compound it simply because it is more affordable than the brand product. Each prescription must document a clinical reason the brand-name product does not meet the patient's needs.
The result is a more constrained legal landscape for compounded tirzepatide than existed in 2023. Telehealth platforms that previously sold compounded tirzepatide based purely on cost-savings no longer have a clean legal pathway. Platforms operating today emphasize the patient-specific clinical need framework and document each prescription accordingly.
This regulatory environment continues to evolve. Patients considering compounded tirzepatide should check the FDA shortage list status and confirm with their telehealth provider that the prescription complies with current FDA guidance.
How to verify a legitimate compounding pharmacy
A legitimate tirzepatide compounding pharmacy should meet several markers.
State pharmacy license. Verify the pharmacy's license number on the state board of pharmacy website. Each state maintains a public lookup tool. The license must be active and in good standing.
FDA registration (for 503B). 503B outsourcing facilities are listed on the FDA's public registered outsourcing facility list. If a pharmacy claims 503B status, search the FDA list to confirm.
USP <797> compliance. Sterile compounding must follow USP <797>. The pharmacy should be able to provide documentation of its cleanroom certification, environmental monitoring records, and personnel training.
API source documentation. A reputable pharmacy uses USP-grade tirzepatide API from FDA-registered suppliers and provides a Certificate of Analysis on request.
Independent third-party testing. Many legitimate compounders publish recent test results (sterility, endotoxin, potency) for their tirzepatide product on their website or share them on request.
PCAB or NABP accreditation (optional but a good sign). The Pharmacy Compounding Accreditation Board (PCAB) and the National Association of Boards of Pharmacy (NABP) offer voluntary accreditation programs for compounding pharmacies. Accreditation is a positive signal but not a legal requirement.
Licensed prescriber on file. The prescription must be written by a U.S.-licensed physician, nurse practitioner, or physician assistant who has evaluated the patient. Compounding without a valid prescription is not legal.
Red flags to avoid
Several warning signs typically indicate a non-compliant or unsafe compounder.
Selling without a prescription. Any website that ships tirzepatide without requiring a prescription is operating outside U.S. pharmacy law. This includes sites that bundle a perfunctory medical questionnaire without an actual licensed provider review.
API sourced from unknown or unverified suppliers. Tirzepatide produced from research-grade or unverified API may contain impurities, incorrect peptide sequences, or contaminants. The price is often significantly lower than legitimate compounders, which is a tell.
No state pharmacy license verifiable. Pharmacies must be licensed in the state where they operate and typically also in states where they ship. Inability to verify a license on the state board website is a red flag.
No physical address. A reputable compounding pharmacy has a verifiable physical address. P.O. boxes or only an email contact are warning signs.
Claims of "FDA approval." Compounded tirzepatide is not FDA-approved. Any pharmacy or telehealth platform claiming otherwise is making a false statement.
Bulk shipments to multiple patients without prescriptions. This is a sign of operating outside the 503A or 503B framework and crosses into unapproved drug manufacturing.
Products from outside the United States. Imported "tirzepatide" from international sources, particularly through online vendors, is often counterfeit or research-grade. The FDA prohibits importation of unapproved drugs into the United States.
For a deeper look at safety considerations with compounded peptides, see our compounded tirzepatide expiration guide.
Cost difference vs brand Mounjaro and Zepbound
The pricing gap between compounded tirzepatide and brand-name tirzepatide is substantial.
| Product | Typical 30-day cash price |
|---|---|
| Compounded tirzepatide (telehealth platform, 503A) | $200 to $500 |
| Mounjaro (Eli Lilly, all dose strengths) | $1,000 to $1,200 |
| Zepbound (Eli Lilly, all dose strengths) | $1,000 to $1,300 |
| Zepbound vials (Lilly Direct, self-pay program) | $349 to $499 |
The cost difference reflects multiple factors:
- Brand-name production has fixed manufacturing capacity and pricing set by Eli Lilly.
- Compounded tirzepatide is produced from bulk API at lower per-dose cost.
- Compounded products do not carry the brand-name premium associated with FDA approval, clinical trials, and patent protection.
The Lilly Direct vial program launched in 2024 narrowed the gap somewhat by offering self-pay patients access to brand tirzepatide vials at $349 to $499 per month. This is still typically higher than compounded prices but closer than the standard pen pricing.
For more on cost comparisons, see our Ozempic cost guide.
Storage, shipping, and shelf life of compounded tirzepatide
Compounded tirzepatide is shipped from the pharmacy to the patient, often via overnight or two-day cold-chain shipping with insulated packaging and gel packs.
Storage: unopened compounded tirzepatide vials are stored at 36 to 46°F (2 to 8°C). Do not freeze.
Shelf life: beyond-use dates (BUDs) are set by the compounding pharmacy based on USP <797> guidelines. Typical BUDs for compounded tirzepatide:
- Sterile aqueous solution refrigerated: 28 to 90 days, depending on preservative status and stability testing
- Reconstituted from lyophilized powder: 28 days refrigerated, generally
- Single-use small-batch preparations: shorter BUDs (typically 14 days)
After first puncture: the vial is good for the BUD on the label, typically 28 days when refrigerated. Some pharmacies stamp 21 days. The shorter window applies if the formulation does not contain a preservative.
Shipping: insulated packaging with gel packs maintains the cold chain for 24 to 48 hours. Vials should not be left at room temperature for extended periods after delivery. Refrigerate immediately upon receipt.
Travel: insulated bag with frozen gel packs, never direct ice. The peptide degrades on freezing.
Color: clear and colorless to faint straw-yellow is normal. Some compounders add vitamin B12 (cyanocobalamin), which produces a pink or red tint. Cloudiness, particles, or unusual discoloration are reasons to call the pharmacy.
FAQ
What is a tirzepatide compounding pharmacy? A tirzepatide compounding pharmacy is a state-licensed pharmacy that prepares custom tirzepatide injection in response to an individual patient prescription. The pharmacy uses USP-grade active pharmaceutical ingredient and follows USP <797> sterile compounding standards. Compounded tirzepatide is not FDA-approved.
Is compounded tirzepatide the same as Mounjaro or Zepbound? No. Mounjaro and Zepbound are FDA-approved brand-name tirzepatide products manufactured by Eli Lilly. Compounded tirzepatide is prepared by a compounding pharmacy under different regulations and is not FDA-approved or interchangeable with the brand products.
Is compounded tirzepatide legal? Compounded tirzepatide is legal under specific conditions. After the FDA removed tirzepatide from the shortage list in October 2024, 503A pharmacies can compound it under the patient-specific clinical need exception, and 503B facilities face additional restrictions. The legal landscape continues to evolve.
What is the difference between 503A and 503B compounding? 503A pharmacies prepare medications for specific patients based on individual prescriptions and are regulated primarily by state boards of pharmacy. 503B outsourcing facilities are FDA-registered, follow cGMP standards, and can produce in larger batches under specific FDA exemptions.
How is compounded tirzepatide priced compared to Mounjaro? Compounded tirzepatide typically costs $200 to $500 per month at telehealth platforms, compared to $1,000 to $1,200 per month for Mounjaro at retail cash prices. The Lilly Direct vial program offers brand tirzepatide at $349 to $499 per month for self-pay patients.
Can compounded tirzepatide be sent across state lines? 503A pharmacies have limited interstate shipping, generally 5% of total prescriptions or as state law allows. 503B facilities can ship interstate without per-prescription limits but must follow FDA cGMP standards. Most legitimate telehealth platforms work with pharmacies licensed in the patient's state.
How long is compounded tirzepatide good for? Beyond-use dates vary by formulation. Typical refrigerated shelf life for sterile aqueous tirzepatide solutions is 28 to 90 days. Always follow the BUD printed on your specific vial label.
Is compounded tirzepatide tested for purity? Legitimate 503A pharmacies often perform sterility, endotoxin, and potency testing on their products. 503B facilities are required to perform additional cGMP-level testing. Ask your pharmacy or telehealth provider for documentation.
What happens if I order compounded tirzepatide from a website without a prescription? Operating without a prescription is outside U.S. pharmacy law. Products sold this way may contain unverified API, contaminants, or incorrect peptide sequences. Patients who use these products take on safety risks not present with legitimately prescribed compounded tirzepatide.
Can I switch from compounded tirzepatide to brand Mounjaro or Zepbound? Yes, with a new prescription from your provider. Most patients who switch start at the same milligram dose they were on with compounded and continue the standard 4-week step-up schedule. Confirm timing with your prescriber.
Are compounded peptides ever the same as brand-name drugs? No, by FDA definition. Even when the active ingredient is identical, compounded products are not FDA-approved, have not gone through the same review process, and are not interchangeable with brand products under federal law.
How do I find a reputable tirzepatide compounding pharmacy? Verify state pharmacy license, FDA registration (for 503B), USP <797> compliance, API source documentation, and ideally PCAB or NABP accreditation. Avoid websites that sell without a prescription or claim FDA approval for compounded products.
Sources
- U.S. Food and Drug Administration. Drug shortage list, tirzepatide entry, accessed Q1 2026.
- U.S. Food and Drug Administration. Compounding and FDA, 503A and 503B compounding sections. 2024.
- Federal Food, Drug, and Cosmetic Act, sections 503A and 503B.
- United States Pharmacopeia. USP General Chapter <797>: Pharmaceutical Compounding, Sterile Preparations. 2023 edition.
- United States Pharmacopeia. USP General Chapter <795>: Pharmaceutical Compounding, Non-sterile Preparations. 2023 edition.
- U.S. Food and Drug Administration. Registered outsourcing facility list, accessed Q1 2026.
- Drug Quality and Security Act of 2013. Public Law 113-54.
- Pharmacy Compounding Accreditation Board. Standards for sterile compounding accreditation. 2024.
- National Association of Boards of Pharmacy. Verified Pharmacy Program standards. 2024.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. SURMOUNT-1. N Engl J Med. 2022;387:205-216.
- Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. SURPASS-2. N Engl J Med. 2021;385:503-515.
Footer disclaimers (all 4 verbatim)
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.